drugset
drugset / Trial / NCT03875157

Study of IBI318 in Participants With Advanced Malignancies

NCT03875157 ↗

Phase 1 Completed 103 enrolled Innovent Biologics (Suzhou) Co. Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open label, multicenter, phase Ia/Ib study to evaluate the safety, tolerability, and initial efficacy of IBI318 in the treatment of patients with advanced malignancies.

Timeline

Start
2019-04-19
Primary completion
2023-02-16
Completion
2023-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI318 Unknown 0.3 mg Intravenous
Subject IBI318 Unknown 1 mg Intravenous
Subject IBI318 Unknown 3 mg Intravenous
Subject IBI318 Unknown 10 mg Intravenous
Subject IBI318 Unknown 30 mg Intravenous
Subject IBI318 Unknown 100 mg Intravenous
Subject IBI318 Unknown 300 mg Intravenous
Subject IBI318 Unknown 600 mg Intravenous

Indications

cancer